Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Prospect Capital Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.03% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PSEC | |
|---|---|---|
Market Cap | $8.02B | $1.14B |
Sector | Health | Financials |
52-Week High | $339.75 | $3.47 |
52-Week Low | $241.71 | $2.15 |
Enterprise Value | $7.84B | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
PSEC trades at $2.25, down 0.44% recently, with a bearish technical signal and neutral oscillators. The company shows mixed fundamentals with a low P/B of 0.39 and consistent earnings beats in recent quarters, but negative revenue of -$407M and net income margin of -495.94% for 2025 highlight financial stress. Recent news includes a new investment in ShipOffers and ongoing dividend payments, though sentiment is cautious amid a deep discount to NAV.
The outlook remains challenging due to persistent negative revenue and high yield risks, but the valuation discount and earnings beats offer potential for value investors. Key risks include further NAV erosion and dividend sustainability, while institutional sentiment is divided with 25% buy ratings against 55% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
